Last reviewed · How we verify
NCT07462299
NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy
NA trial testing NUDT15/TPMT genotype-guided 6-MP dosing in Childhood Acute Lymphoblastic Leukemia in 110 participants. Not yet recruiting.
1 January 2028
Quick facts
| Lead sponsor | The Children's Hospital of Zhejiang University School of Medicine |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 20 February 2026 |
| Primary completion | 1 January 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- NUDT15/TPMT genotype-guided 6-MP dosing — full drug profile →
Conditions studied
- Childhood Acute Lymphoblastic Leukemia — all drugs for Childhood Acute Lymphoblastic Leukemia →
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Who can join
Adults 1 to 18, any sex, with Childhood Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single-center clinical study to evaluate the safety and efficacy of a personalized 6-mercaptopurine (6-MP) dosing strategy guided by NUDT15 and TPMT genotypes in children with Acute Lymphoblastic Leukemia (ALL) during maintenance therapy. The study compares this gene-guided strategy with historical controls to assess if it reduces the incidence of Grade ≥3 neutropenia and infection events.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07462299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Childhood Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT07071051 — Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Pat · recruiting
- NCT06575296 — Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant · Phase 1 · recruiting
Other The Children's Hospital of Zhejiang University School of Medicine trials
Trials by the same sponsor.
- NCT07368504 — AI for Newborn Metabolic Screening · NA · not yet recruiting
- NCT07499154 — Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery · Phase 4 · not yet recruiting
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07496541 — Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis · not yet recruiting
- NCT07045844 — Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07462299 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Children's Hospital of Zhejiang University School of Medicine
- Last refreshed: 10 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07462299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing